What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from the CLIMB-THAL-111 trial shows that exa-cel achieves transfusion independence in 92.9% of participants after 12 months, indicating a moderate benefit over current care. However, the follow-up duration was relatively short, and the treatment was not compared directly with other therapies, which limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for exa-cel are highly uncertain, with some scenarios exceeding NICE’s acceptable thresholds. Although the treatment has potential cost-saving implications, the uncertainties in long-term effects and quality of life outcomes raise concerns about its overall economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
While there are indications that exa-cel may improve quality of life by reducing the need for blood transfusions, the evidence is mixed and primarily derived from indirect comparisons. The utility values used in the economic model are uncertain, and further data collection is needed to confirm these effects.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Exa-cel has a good safety profile, with manageable adverse events reported in the clinical trial. The treatment’s adverse effects appear to be comparable to or better than existing therapies, indicating acceptable safety.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was not compared directly with other therapies in the clinical trial, which limits the robustness of the evidence. An indirect comparison was made with standard care, but the lack of head-to-head data raises concerns about the validity of the findings.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, with a median age of 20 years and a diverse demographic. However, there are some limitations in subgroup analyses that could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Exa-cel can be integrated into existing healthcare pathways with minor adjustments, such as additional training for staff involved in the treatment process. The treatment process is feasible within current clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment may lead to a high resource burden due to its cost and the need for additional monitoring. While it has potential cost-saving implications, the overall budget impact remains uncertain.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from a single trial with some methodological concerns. While the trial provides promising results, the overall robustness of the evidence is limited due to the lack of long-term follow-up and direct comparisons.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effects of exa-cel, particularly concerning its durability and impact on quality of life. The committee noted that further data collection is necessary to address these uncertainties.
